Interv Akut Kardiol. 2005;4(4):192-193

Acetylsalicylic acid resistance

Jaroslav Malý
I. interní klinika Fakultní nemocnice v Hradci Králové

Definice rezistence na kyselinu acetylsalicylovou (ASA) má svá úskalí, protože v sobě spojuje klinická a laboratorní kritéria. Rezistence na kyselinu acetylsalicylovou je definována jako neschopnost ASA bránit účinně kardiovaskulárním trombotickým komplikacím přes to, že ASA je řádně užívána. Dále jako neschopnost mít vliv na laboratorní testy, které umožňují sledovat destičkovou aktivitu (12). Je zajímavé, že již v roce 1966 Quick definoval ASA rezistenci jako neschopnost prodlužovat krvácivost u nemocných s vonWillebrandovou chorobou po podání ASA. Definovat rezistenci na ASA je obtížné, protože se definice vztahuje ke klinickému efektu ASA, nikoliv jen k laboratorní kontrole účinku ASA in vitro (3). V tabulce 1 jsou uvedeny faktory, které mohou ovlivňovat ASA rezistenci.

Keywords: -

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malý J. Acetylsalicylic acid resistance. Interv Akut Kardiol. 2005;4(4):192-193.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andersen K, Hurlen M, Arbesem H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 37-42. Go to original source... Go to PubMed...
    2. Buchanan MR, Bister SJ.: Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can. J. Cardiol. 1995; 11: 221-227.
    3. Bultas J, Karetová D. Léčba trombotických stavů - kde jsme a kam se ubíráme. Remedia 2004; 14, 2: 182-200.
    4. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarcion, stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation 2002; 105: 1650-1655. Go to original source... Go to PubMed...
    5. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol. 2003; 41, 6: 966-968. Go to original source... Go to PubMed...
    6. Gum PA, Kottke Marchant K, Poggio ED, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease, Am. J. Cardiol 2001; 88: 230-235. Go to original source... Go to PubMed...
    7. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41, 6: 961-965. Go to original source... Go to PubMed...
    8. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994; 25, 12: 2331-2336. Go to original source... Go to PubMed...
    9. Chen WH, Lee PY, Ng W, et al. Aspirin resistence in associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despote clopidrogel pretreatment. J Am Coll Cardiol, 2004; 43: 1122-1126. Go to original source... Go to PubMed...
    10. Lee PY, Chen WH, Ng W, Cheby X, Kwok JY, Tse HF, Lau CP. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am. J. Med. 2005; 118, (7): 723-727. Go to original source... Go to PubMed...
    11. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Blizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-49. Go to original source... Go to PubMed...
    12. Malý J. Vyšetření aktivity destičkových funkcí se vztahem k rezistenci na kyselinu acetylsalicylovou Vnitřní Lék. 2005; 51, 2: 157-162.
    13. McKee SA, Sane DC, Dellargyris EN. Aspirin resistance in cardiovascular diseases: A review of prevalence, mechanisms and clinical significance. Thromb. Haemost. 2002; 88: 711-715. Go to original source... Go to PubMed...
    14. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the working group on aspirin resistance. Journal of. Thromboisn and Haemostasis. 2005; 3: 1309-1311. Go to original source... Go to PubMed...
    15. Patrono C. Aspirin resistance: definition, mechanism and clinical read-outs. J. Tromb. Haemost. 2003; 1: 1710-1713. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.